Wegovy delivery update: what the new 48-hour temperature approval means for Pharmulous patients

Wegovy delivery update: what the new 48-hour temperature approval means for Pharmulous patients

If you receive Wegovy through Pharmulous, there has been an important update to how the medication can be transported.

Wegovy has now been approved for controlled-temperature delivery for up to 48 hours below 30°C. For Pharmulous patients, this is reassuring news. It means delivery can be more flexible and practical, while still remaining within approved conditions. Novo Nordisk announced this as a first for a GLP-1 weight-loss treatment in the EU, and UK patients should continue to rely on approved product information and regulatory guidance for safe use and storage.

What has actually changed?

The update is specifically about transport and delivery. In practical terms, it gives providers more flexibility when getting Wegovy safely to patients. For Pharmulous, this helps support a more practical and reliable home-delivery model, while still working within the approved parameters for transport.

Many patients understandably associate injectable medicines with strict refrigeration at every stage. This update helps ease some of that concern by confirming that Wegovy can be transported within approved controlled conditions for up to 48 hours, provided temperatures remain below 30°C.

Does this mean Wegovy no longer needs refrigeration?

No.

This change is about approved delivery conditions, not a wholesale change to the storage advice patients should follow themselves. If you receive Wegovy from Pharmulous, you should still read the leaflet supplied with your medication and follow the official storage instructions, along with any advice given by our prescribers or pharmacy team. The MHRA product record and the approved patient leaflet remain the key references for safe use and storage.

Why this is helpful for Pharmulous patients

For Pharmulous patients, the biggest benefit is convenience and reassurance. A more flexible approved delivery window supports smoother home delivery and helps patients feel more confident about how their treatment reaches them.

At Pharmulous, we know that patients want confidence not only in whether a treatment is suitable for them, but also in how it is supplied, stored, and handled safely. This update supports the kind of modern pharmacy delivery pathway patients increasingly rely on, while keeping patient safety at the centre. The MHRA also advises that GLP-1 medicines should only be obtained through legitimate, regulated channels.

What should you do when your Wegovy arrives from Pharmulous?

Even with the updated transport approval, it is still sensible to bring your parcel indoors promptly, check that the packaging appears intact, and read the instructions supplied with the medication.

If anything seems unclear, damaged, or unexpected, please contact the Pharmulous team before using the pen. Using a regulated pharmacy provider and following official product guidance remains the safest approach.

Wegovy delivery update: FAQs

Can Pharmulous now deliver Wegovy without full cold-chain transport?

Wegovy can now be transported under approved controlled conditions below 30°C for up to 48 hours during delivery. This approval is specifically relevant to transport and delivery arrangements.

Does this change how I store Wegovy at home?

No. If you receive Wegovy from Pharmulous, you should continue to follow the storage instructions provided with your medication and any advice from our pharmacy team or prescribers.

Is this relevant for UK patients ordering through Pharmulous?

Yes. UK patients should continue to rely on approved product information and regulatory sources, including MHRA-linked product records and the official patient leaflet, for current guidance.

Is this good news for Pharmulous patients receiving Wegovy by home delivery?

Yes. In practical terms, it supports more flexible and reliable delivery for patients using a home-delivery pharmacy service.

Should I worry if my Wegovy arrives by courier from Pharmulous?

Not necessarily. If your medication has been supplied by a regulated provider and handled within approved delivery conditions, that is consistent with the updated transport rules. If you are unsure, the safest step is to contact the Pharmulous team before use. The MHRA also advises patients to obtain GLP-1 medicines only through legitimate, regulated suppliers.

Ultimately

This latest update is a positive development for Pharmulous patients using Wegovy. The approval for controlled-temperature delivery below 30°C for up to 48 hours helps make home delivery more practical and reassuring, while the usual storage instructions remain just as important as before.

At Pharmulous, our priority remains to supply treatment safely, appropriately, and through regulated clinical processes. If you have any questions about Wegovy delivery, storage, or treatment suitability, our team is here to help.

Sources

• Novo Nordisk – Wegovy becomes first GLP-1 weight-loss treatment approved for 48-hour controlled-temperature delivery in the EU
• MHRA – Wegovy product search
• MHRA – GLP-1 medicines for weight loss and diabetes: what you need to know
• Wegovy patient leaflet – electronic medicines compendium
• PharmiWeb – Wegovy approved for 48-hour controlled-temperature delivery